Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Brain Neoplasms 6Glioma 3Glioblastoma 2Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Neuroma, Acoustic 1Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Cerebrovascular Disorders 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × Fluorescein × CNS × Clear all
NCT03291977 2022-11-09

FLEGME

Rennes University Hospital

Phase 3 Completed
51 enrolled
CNS

Glioblastoma

NCT02540135 2018-07-20

Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma

University of Colorado, Denver

Phase NA Withdrawn
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡